Health care
Previous3/18/2013 4:38:24 AM - 4/3/2013 12:19:29 AMNextReturn to Sitemap
- Novartis says Alcon's eye drug Jetrea gets EU approval
- Health agencies warn of global TB threat, funding gap
- Analysis: Antibiotics crisis prompts rethink on risks, rewards
- Arkansas health plan for poor to add limited federal costs: report
- Amerisource signs distribution, equity deal with Walgreen
- FDA reviewers say Titan drug dose may be insufficient
- FDA names Kathleen Uhl acting director, office of generic drugs
- Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera
- Mississippi forbids local laws on nutrition, super-size drinks
- Valeant to buy Obagi Medical for about $344 million
- Older fathers more likely to have autistic grandchildren
- U.S. autism estimates climb to 1 in 50 school-age children
- U.S. TB rates reach all-time low, but resistance a threat
- U.S. pediatricians back gay marriage, adoption rights
- Supreme Court to decide on deals to delay cheaper drugs
- EU backs MS drugs from Biogen, Sanofi; Gilead HIV pill
- Biogen wins EU backing for big new MS drug hope
- FDA suggests charging fees to pay for oversight
- Top U.S. court to decide on deals to delay cheaper drugs
- J&J recalling more than 2 million blood glucose meters worldwide
- Supreme Court justices signal uncertainty on drug settlements
- Lundbeck to develop, sell Alzheimer's drug with Otsuka
- Little hope seen for millions priced out of health overhaul
- China's "black clinics" flourish as government debates health reform
- Death toll from new virus reaches 11: U.N. health body
- AP Pharma's drug for chemotherapy-induced nausea denied approval
- Biogen prices new MS drug at discount to key competitors
- U.S. to reexamine health effects of cellphone radio waves
- India's top court dismisses Novartis plea for Glivec patent
- FDA loosens restrictions on nicotine replacement products
- After "Tan Mom," New Jersey bans children from tanning beds
- Federal government slashes New York's Medicaid payments
- Analysis: Big Pharma down, not out, after Indian patent blow